Fernando Casal

CiQUS (USC) aimed at generating groundbreaking science at the intersection of Chemistry, Biology & Materials Science. We comprise 18 research groups and over 200 people, which were awarded 12 ERC projects (4 ERC-PoC). CiQUS reached almost 10 MEUR/year (2021-2023) in competitive funds, and an Impact Factor of 9.5 (JCR, 2022). Key Words \- Biomed: • Drug & nuclei acid delivery: non-immunogenic peptide carriers, stimuli-responsibe hybrid nanocomposites, MOFs, dendrimers...); • New catalytic nanomaterials in living settings; • Fluorescent tools in drug discovery; • Molecular dynamics; • Bio-supramolecular chemistry & nanotechnology; Check our Tecnology Offers. EU Projects \- Biomed (check all our Research projects): • EIC-Transition “TraffikGene-Tx”: Targeted Peptide Carriers for RNA Delivery. • EIC-Pathfinder “CAR T-REX”: CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment. • CaixaResearch Consolidate 2021: Eliminating cancer stem cells: inhibition of mitochondrial respiration. • AECC 2021: Anticancer drugs: selective cleavage of DNA three-way junctions by CU(II) peptide. • AECC 2020: Novel vaccine approach for cancer immunotherapy based on protein microspheres. • Adjuvant-free subunit vaccines for COVID-19 (Funds: ISCII – Spain & European Vaccine Initiative). • FET-OPEN “SWIMMOT”: Switchable magneto-plasmonic contrast agents and molecular imaging. • H2020-ICT “REAP”: Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacustic tomography. • H2020-SC1 "ENDOSCAPE": Clinically applicable non-viral gene delivery technology”. • ERC-PoC “antiCSC”: Targeting the cancer stem cell metabolism with reactive metal complexes.